Section 6 of 6
References
62 sources
- American Cancer Society (2026) (opens in a new tab)
- ASCO (2022) (opens in a new tab)
- ASCO (2023) (opens in a new tab)
- Ashouri et al. (2025) (opens in a new tab)
- Bhimani et al. (2022) (opens in a new tab)
- Blank et al. (2011) (opens in a new tab)
- Burge et al. (2026) (opens in a new tab)
- Cann et al. (2026) (opens in a new tab)
- Cayman Chemical (2025) (opens in a new tab)
- Centers for Disease Control and Prevention about colorectal cancer page (opens in a new tab)
- Centers for Disease Control and Prevention colorectal cancer risk factors page (opens in a new tab)
- Centers for Disease Control and Prevention colorectal cancer symptoms page (opens in a new tab)
- Dasari et al. (2023) (opens in a new tab)
- Dauki et al. (2026) (opens in a new tab)
- Eng et al. (2019) (opens in a new tab)
- EU Clinical Trials Register EudraCT 2021-003243-21 (opens in a new tab)
- Exelixis access to investigational therapies policy (opens in a new tab)
- Exelixis clinical trials pipeline (opens in a new tab)
- Exelixis first quarter 2026 Form 10-Q (2026) (opens in a new tab)
- Exelixis Form 10-K (2026) (opens in a new tab)
- Exelixis Form 8-K (2026) (opens in a new tab)
- Exelixis new drug application acceptance announcement (2026) (opens in a new tab)
- Exelixis second quarter 2026 Form 10-Q (2026) (opens in a new tab)
- Exelixis STELLAR-001 results announcement (2025) (opens in a new tab)
- Exelixis STELLAR-303 detailed results announcement (2025) (opens in a new tab)
- Exelixis STELLAR-303 healthcare professional brochure (2023) (opens in a new tab)
- Exelixis STELLAR-303 topline results announcement (2025) (opens in a new tab)
- Exelixis STELLAR-303 update announcement (2026) (opens in a new tab)
- FDA (2026) (opens in a new tab)
- FDA fruquintinib approval announcement (2023) (opens in a new tab)
- FDA nivolumab with ipilimumab approval announcement (2025) (opens in a new tab)
- FDA sotorasib with panitumumab approval announcement (2025) (opens in a new tab)
- FDA trifluridine and tipiracil with bevacizumab approval announcement (2023) (opens in a new tab)
- FDA tucatinib with trastuzumab accelerated approval announcement (2023) (opens in a new tab)
- Fontana et al. (2025) (opens in a new tab)
- Garmezy et al. (2025) (opens in a new tab)
- Grothey et al. (2013) (opens in a new tab)
- Guven et al. (2024) (opens in a new tab)
- Hecht et al. (2025) (opens in a new tab)
- Hsu et al. (2021) (opens in a new tab)
- Hsu et al. (2023) (opens in a new tab)
- Kawazoe et al. (2024) (opens in a new tab)
- Kiel et al. (2026) (opens in a new tab)
- Morris et al. (2022) (opens in a new tab)
- National Cancer Institute Colon Cancer Treatment PDQ (opens in a new tab)
- National Cancer Institute Drug Dictionary (opens in a new tab)
- National Cancer Institute SEER Cancer Stat Facts (opens in a new tab)
- Paly et al. (2024) (opens in a new tab)
- Patnaik et al. (2021) (opens in a new tab)
- Prager et al. (2023) (opens in a new tab)
- Rasschaert and Tejpar (2025) (opens in a new tab)
- Saeed et al. (2024a) (opens in a new tab)
- Saeed et al. (2024b) (opens in a new tab)
- Saeed et al. (2025) (opens in a new tab)
- Shankaran et al. (2022) (opens in a new tab)
- Sharma et al. (2022) (opens in a new tab)
- Stintzing et al. (2025) (opens in a new tab)
- Strohbehn et al. (2026) (opens in a new tab)
- Taieb et al. (2025) (opens in a new tab)
- Yoshino et al. (2023) (opens in a new tab)
- Yoshino et al. (2023) (opens in a new tab)
- Yu et al. (2024) (opens in a new tab)